<DOC>
	<DOCNO>NCT00536770</DOCNO>
	<brief_summary>The purpose study determine safety efficacy investigational study drug DN-101 ( calcitriol ) give combination gemcitabine ± erlotinib treatment pancreatic cancer .</brief_summary>
	<brief_title>A Study Gemcitabine ± Erlotinib DN-101 Versus Gemcitabine ± Erlotinib Placebo Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis locally advance unresectable , metastatic pancreatic cancer Performance status 0 , 1 , 2 Adequate bone marrow , renal hepatic function Prior chemotherapy radiation therapy pancreatic cancer Prior treatment cancer last 6 month Cancer brain spine Active uncontrolled infection Hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>